Abbott Laboratories is presented as a superior alternative to volatile cannabis stocks like Tilray, offering 54 consecutive years of dividend increases and expected 10% EPS growth in 2026. The company benefits from its pending $23 billion acquisition of Exact Sciences and new FDA-approved heart rhythm treatment, though it faces headwinds from FreeStyle Libre 3 product issues and flat diagnostics segment performance.

MDxHealth SA (NASDAQ: MDXH), a precision diagnostics company, announced it will release its fourth quarter and full year 2025 financial results on February 26, 2026, followed by a conference call. The company also reported preliminary 2025 revenues, issued 2026 guidance, and amended earnout terms with Exact Sciences. Additionally, MDxHealth is collaborating with the University of Oxford to validate its GPS test in a large randomized trial for localized prostate cancer treatment.

Abbott Laboratories' stock fell nearly 10% after missing Q4 revenue expectations due to higher manufacturing costs in its nutrition segment. However, the analyst argues the sell-off was overdone, citing Abbott's strong EPS growth, accelerating 2026 revenue guidance (6.5-7.5% organic growth), diversified portfolio, and pending acquisition of Exact Sciences expected to close in Q2 2026, which could add a new cancer detection growth vertical.

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, missing consensus expectations of $11.80 billion. The company issued disappointing guidance for Q1 2026 and fiscal 2026, projecting adjusted earnings below Wall Street estimates. The stock fell 7.37% to a new 52-week low following the announcement.

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties related to their merger or acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.

Investor rights law firm Halper Sadeh LLC is investigating three companies for potential federal securities law violations and breaches of fiduciary duties related to their merger transactions: Sealed Air's sale to CD&R funds for $42.15 per share, Exact Sciences' acquisition by Abbott for $105.00 per share, and Olympic Steel's merger with Ryerson Holding Corporation. The firm is seeking increased consideration for shareholders and additional disclosures.

MDxHealth reported preliminary 2025 revenues of $109 million (21% YoY growth) with Q4 revenues of $30.5 million (23% YoY growth). The company issued 2026 revenue guidance of $137-140 million (26-28% growth) and expects to achieve a 10% adjusted EBITDA margin run rate by year-end 2026. MDxHealth amended its earnout obligations with Exact Sciences, deferring payments to 2026-2028 and issuing 3 million warrant shares at $5.265 per share.

The global gastrointestinal diagnostics market is projected to grow from $4.9 billion in 2024 to $5.8 billion by 2030, driven by rising GI disorder incidence, advanced imaging technologies, and non-invasive diagnostic methods.

Adaptive Biotechnologies' stock dropped after Natera acquired Foresight Diagnostics for $275 million upfront, raising competitive concerns in the blood-cancer minimal residual disease (MRD) market.

Abbott Laboratories announced a $21 billion acquisition of Exact Sciences, a cancer diagnostic specialist, to expand its diagnostics business and enter the cancer screening market with innovative products like Cologuard.

The Pre-Dx oncology market is entering a high-growth phase, driven by breakthrough non-invasive cancer detection technologies like liquid biopsy and multi-cancer early detection tests. The market is expected to generate substantial revenue growth, with North America leading and Asia Pacific showing the fastest growth potential.

Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies involved in recent merger and acquisition transactions.